Prevalence of Co-morbidities in Patients with Pulmonary Tuberculosis at 5th of Azar Hospital of Golestan Province of Iran (2001-2005) "Research Center for Infectious and Parasitic Diseases"

Document Type : Research Paper


1 Assistant professor of Infectios Disease, Golestan Univerity of Medical Sciences,Golestan, Iran

2 Golestan Univerity of Medical Sciences,Golestan, Iran

3 General practitioner


Golestan has the second highest prevalence of tuberculosis in Iran. We conducted this study to evaluate the frequency of coexisting medical conditions and their effects on some epidemiologic factors in patients with tuberculosis in this area.
Materials and Methods
In a cross-sectional descriptive study we checked the records of all patients (older than 13 years) admitted during period 2001 to 2005 with pulmonary tuberculosis at 5th of Azar hospital of Gorgan, Iran. Demographic information, age, sex, time of admission at the hospital and coexisting medical conditions (diabetes, chronic renal failure, corticosteroids consumption and malignancies) were extracted from the patient's file. Chi-square test and Fisher exact test were used for statistical analysis.
We studied 243 patients with pulmonary tuberculosis, during 5 years. The mean age of the patients was 50.15 years (SD=19 years). Of total, 162 cases (66.7%) had not any Co-morbidity. Diabetes mellitus was the most prevalent condition with an overall prevalence of 23.05 percent. Co-morbidity of tuberculosis and diabetes was significantly higher in females than males (p<0.05).
Our results suggest that patients with co-morbidities (such as diabetes) and respiratory signs should be assessed for pulmonary tuberculosis. Also, in the patients with pulmonary tuberculosis, diabetes screening should be considered.


1- Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases. 6th ed. New York: Churchill
Livingstone; 2005.Vol 4. p. 2863-66.
2- Center for disease control and prevention statement from the center for disease control and prevention in response to
WHO world TB day Atlanta GA: CDC update, 1998.
3- Anonymous. Tuberculosis in compromised hosts. Kekkaku 2003; 78:717-722.
4- Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial 2003; 16: 38-44.
5- Nissapathorn V, Kuppusamy I, Josephine FP. Tuberculosis. A resurgent disease in immunosuppressed patients.
Southeast Asian J Trop Med Public Health 2006;37:153-160.
6- Ponce-De-Leon JL,Olaiz-Fernandez G, Rojas J. Tuberculosis and diabetes in southern Maxico.Diabetes Care
7- Bacakoglu F, Basoglu OO, Cok G. Pulmonary tuberculosis in patients with diabetes mellitus. Respiration 2001; 68:
8- Stevenson CR, Critchley A, Forouhi NCC. Diabetes and the risk of tuberculosis: a neglected threat to public health.
Chronic Illn 2007; 3:228-245.
9- Kobashi Y, Matsushima T. Clinical analalysis of pulmonary tuberculosis in association with corticosteroid therapy.
Intern Med 2002; 41:1103-1110.
10- Pal D, Behera D, Gupta D. Tuberculosis in patients receiving prolonged treatment with oral corticosteroids for
respiratory disorders. Indian J Tuberc 2002; 49: 83-86.
11- Pandey M, Abraham EK, Chandramohan K. Tuberculosis and metastatic carcinoma coexisting in axillary
lymphnode: a case report. World J surg Oncol 2003;1:1-3.
12- Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis 2006; 42:1592-1595.
13- htpp: //
14- Tubercolusis. Bulletin of the National TB day. Center for Diseases Control (CDC), Iranian Ministry of Health and
Medical Education; 2004.
15- Global tuberculosis control, surveillance, planning, financing. WHO report 2002. Geneva: World Health
Organization; 2002.
16- Vasankari T, Holmstrom P, Ollgren J. Risk factors for poor tuberculosis treatment outcome in finland: a cohort
study. BMC Public Health 2007; 7: 291.
17- Abbasi A , Moradi A , Kabir M .Characteristics of pulmonary tuberculosis patients in Golestan province of Iran ,
2000-2005. J Med sci 2006; 6:698-700.
18-Guya MM.Diabetes and hypothyroidism. Annual conference of diabetes and dHypothyroidism screening. Center for
Diseases Control (CDC), Iranian Ministry of Health and Medical Education; 2006.
19- Prez-Guzman C, Vargas MH, Padilla JR. Diabetes modifies the male: female ratio in pulmonary tuberculosis. Int J
Tuberc Lung Dis 2003; 7:354 –358.
20- htpp:// 06/files/28.pdf .
21- Sasaki Y, Yamagishi F, yagi T. A clinical study in the collagen disease patients developed pulmonary tuberculosis
during corticosteroid administration. kekkaku 2000;75: 569-573.
22- Quantrill SJ, Woodhead MI, Bell CE. Side effects of antituberculosis drug treatment in patients with chronic renal
failure. Eur Respir J 2002;20:440-443.
23- Cengiz K. Increased incidence of tuberculosis in patients undergoing hemodialysis . Nephron 1996; 73: 421-424.
24- Karnak D, Kayacan O, Beder S. Reactivation of pulmonary tuberculosis in malignancy. Tumori 2002; 88: 251-254. 
25- Yamagishi F, Suzuki K, Sasaki V. Prevalence of coexisting diabetes mellitus among patients with pulmonary
tuberculosis. Kekkaku 1996; 71:569-572.
26- High rates of tuberculosis in end –stage renal failure: the impact of international migrant. Emerg Infect Dis 2002; 8: 1-4.
27- AL Shohaib S. Tuberculosis in chronic renal failure in Jeddah. J infect 2000; 40: 50-3.
28- Leung ECC, Tam CM. Comorbidities among patients with tuberculosis in Hong Kong. HK Pract 2002; 24: 114-131.
29. AL Jahadi H, AL Zahrani K, Amene p. Clinical aspect of miliary tuberculosis in saudi adults. Int J tuberc lung Dis
2000; 4: 252-255.